PRECISION FOR MEDICINE (UK), LTD

1. PRECISION FOR MEDICINE (UK), LTD 2020-05-27 → present
2. PRECISION FOR MEDICINE & ONCOLOGY (UK), LTD. 2017-03-23 → 2020-05-27

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

Grant Thornton UK LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“In assessing the company's ability to continue as a going concern, the directors have considered the uncertainties associated with both internal and external factors that could impact the company's cash flows, capital, solvency, and liquidity position. Based on this assessment, and with consideration of the support letter obtained, which provides financial backing through the going concern period ending October 31, 2026, the directors are satisfied that the company has adequate resources to continue in operational existence for the foreseeable future. Based on this assessment, the directors believe the company is in a stable position due to its focus on the life sciences sector and has a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future and have obtained confirmation they will be provided with sufficient support from its parent company should it be necessary. The directors have therefore prepared the financial statements on a going concern basis.”

Significant events

• “During the year, the employees of Precision for Medicine (UK Labs), Ltd were transferred to Precision for Medicine (UK), Ltd ahead of the planned hive up.”
• “Effective January 31, 2025, the company completed a reorganisation with the entity Precision for Medicine (UK Labs), LTD in which the net assets of this entity were transferred to the company. This transaction does not constitute a business combination as defined by FRS 102 Section 19 and has been accounted for using the book value method in FY25. The net assets were transferred for no consideration and no goodwill was recorded associated with the reorganisation.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

3

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  +15.2%

  £17,656,616 → £20,332,013

• Cash

  +26.3%

  £2,985,326 → £3,770,627

• Net assets

  +70.3%

  £3,132,153 → £5,333,250

• Employees

  +12.2%

  123 → 138

• Operating profit

  -22%

  £1,547,970 → £1,207,207

• Profit before tax

  -16.4%

  £1,575,771 → £1,317,764

• Wages

  +17.9%

  £9,824,347 → £11,579,510

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers